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ABSTRACT
Objective: To achieve consensus on the most
important outcome domains to measure across all
clinical trials for shoulder disorders.
Methods: We performed an online modified Delphi
study with an international, multidisciplinary and
multistakeholder panel. A literature review and the
OMERACT Filter 2.0 framework was used to generate a
list of potential core domains, which were presented to
patients, clinicians and researchers in two Delphi
rounds. Participants were asked to judge the
importance of each potential core domain and provide
a rationale for their response. A core domain was
defined a priori as a domain that at least 67% of
participants considered core.
Results: In both rounds, 335 individuals were invited
to participate (268 clinicians/researchers and 67
patients); response rates were 27% (n=91) and 29%
(n=96), respectively. From a list of 41 potential core
domains, four domains met our criteria for inclusion:
‘pain’, ‘physical functioning’, ‘global assessment of
treatment success’ and ‘health-related quality of life’.
Two additional domains, ‘sleep functioning’ and
‘psychological functioning’, met the criteria for
inclusion by some, but not all stakeholder groups.
There was consensus that ‘number of deaths’ was not
a core domain, but insufficient agreement on whether
or not several other domains, including ‘range of
motion’ and ‘muscle strength’, were core domains.
Conclusions: Based on international consensus from
patients, clinicians and researchers, ‘pain’, ‘physical
functioning’, ‘global assessment of treatment success’
and ‘health-related quality of life’ were considered core
outcome domains for shoulder disorder trials. The
value of several other domains needs further
consideration.
INTRODUCTION
Shoulder pain is a common, activity-limiting
symptom.1 2 It has various causes, including
rotator cuff disease (most commonly),
adhesive capsulitis and other disorders
of the glenohumeral joint (eg, osteoarthritis,
humeral head fracture).1 3 4 Regardless of
the cause, people with different shoulder dis-
orders tend to experience similar outcomes,
including pain, problems with performing
daily activities such as dressing, reduced par-
ticipation in recreational activities and dis-
rupted sleep patterns.5 6 However, there is a
lack of uniformity in the outcomes measured
in shoulder trials,7 which limits our ability to
compare ﬁndings between studies and syn-
thesise data in meta-analyses.
The Outcome Measures in Rheumatology
(OMERACT)8 and Core Outcome Measures
in Effectiveness Trials (COMET)9 initiatives
have responded to the problem of outcome
Key messages
What is already known about this subject?
▸ There is a lack of uniformity in the outcomes
measured in shoulder trials.
What does this study add?
▸ In a modified Delphi study, a majority of
patients, clinicians and researchers identified
‘pain’, ‘physical functioning’, ‘global assessment
of treatment success’ and ‘health-related quality
of life’ as important domains to include in a core
outcome set (COS) for shoulder disorders.
▸ The value of several other domains, including
‘sleep functioning’, ‘psychological functioning’,
‘range of motion’ and ‘muscle strength’, needs
further consideration.
How might this impact on clinical practice?
▸ Uptake of a COS for shoulder disorders in future
clinical trials should increase our ability to
compare findings between studies and synthe-
sise data in meta-analyses, which may provide
more reliable evidence for decision makers.
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diversity by developing guidance for the creation of core
outcome sets (COSs). A COS is a collection of outcome
domains (true states or endpoints of interest) recom-
mended for measurement in all trials for a particular
condition.9 10 No COS for shoulder disorders currently
exists, so the OMERACT Shoulder Core Outcome Set
Special Interest Group was established to address this
gap.
It is recommended that COS development starts by
identifying, through literature review, a list of poten-
tial domains to measure, which is then reﬁned via con-
sensus processes.9 10 We recently completed a review
of outcome domains and measurement instruments
reported in 409 randomised trials of interventions for
shoulder disorders published between 1954 and
2015.18 We identiﬁed 32 domains across these trials.
The majority included a measure of pain (90%),
range of motion (78%) and physical functioning
(71%), while muscle strength was reported in 44% of
trials, and imaging outcomes were reported in 21% of
trials. Other patient-reported outcome measures
(PROMs) such as health-related quality of life were
each reported in 15% or fewer trials. Most domains
were reported at a similar frequency across different
shoulder disorders.18
Informed by our previous literature review, this paper
presents the results of an international modiﬁed Delphi
study performed to achieve consensus from patients,
clinicians and researchers on which domains should be
included in a COS for all shoulder disorders.
METHODS
Our prespeciﬁed methods are described elsewhere
(Gagnier JJ, Page MJ, Huang H, et al. Creation of a core
outcome set for clinical trials of patients with shoulder
pain: A protocol. Trials 2016. Under review). We prede-
termined that the COS should be applicable to most
common shoulder disorders, including: rotator cuff
disease (an umbrella term to classify disorders of the
rotator cuff muscles or tendons, including subacromial
impingement syndrome, rotator cuff tendinopathy or
tendinitis, partial or full rotator cuff tear, calciﬁc tendin-
itis and subacromial bursitis11); adhesive capsulitis;
shoulder instability; glenohumeral osteoarthritis; disloca-
tion of the shoulder and proximal humeral or humeral
head fractures. It should also be applicable to unspeci-
ﬁed shoulder pain, to capture trials in primary care that
have included people with shoulder pain without a spe-
ciﬁc diagnosis or cause.
We used an international online modiﬁed Delphi
process since it permits involvement of geographically
distant and informed individuals, anonymity of responses
and lack of interaction among participants to prevent the
views of prominent personalities from dominating the
group.12 This project received ethical approval from the
University of Michigan (HUM00102228).
Selection of panel members
One author (HH) made a list of corresponding authors
of all shoulder trials indexed in PubMed from 2006 to
2015 (identiﬁed from our previous literature review).18
Three authors (RB, JJG and APV) nominated other
researchers with expertise in shoulder disorders not
identiﬁed from PubMed, and clinicians from different
disciplines who have clinical experience in managing
people with shoulder disorders. Clinicians could invite
patients to participate if they had a current or had a pre-
vious episode of shoulder pain and understood written
English. Patients were compensated US$25 for comple-
tion of each Delphi round. The ﬁnal list of selected par-
ticipants was kept conﬁdential and known only to the
project team members.
Generation of a list of potential core domains
We reﬁned the initial list of 32 potential core domains
identiﬁed from our previous literature review,18 through
discussion and debate, by considering if there were any
important domains missing and if certain domains were
too broad or should be aggregated. This resulted in 41
domains being generated for inclusion in round one
(table 1; deﬁnitions in online supplementary ﬁle 1, table
S1). The framework endorsed by OMERACT
(‘OMERACT Filter 2.0’) was used to structure the poten-
tial core domains under four core areas of health
(death, life impact, pathophysiological manifestations,
resource use10). However, when selecting the threshold
for inclusion in the COS, there was no requirement that
at least one core domain needed to exist in each of the
core areas. To generate deﬁnitions for each domain, ter-
minology used in a previous Delphi study to develop a
COS for non-speciﬁc low-back pain13 was consulted.
Delphi procedure
Participants were invited via email to complete two
Delphi rounds administered via the online software
SurveyMonkey (SurveyMonkey, Palo Alto, USA; surveys
in online supplementary ﬁles S2 and S3). In both
rounds, we kept the survey available for 2 weeks, and
sent a reminder email 1 week after the initial invitation.
Individuals not participating in the ﬁrst round, who did
not explicitly express their desire to opt out, were
invited to the subsequent round. This modiﬁed Delphi
approach has been used in previous studies.12 13 The
study was fully anonymised, in that participants did not
know the identities of other individuals in the group,
nor the speciﬁc answers that any individual provided.
The ﬁrst round ran from 4 to 18 March 2016.
Participants were asked to judge the importance of each
potential core domain by answering questions phrased
as follows, for example: ‘Is the domain “Overall pain”
important enough to be included in a core domain set
for clinical trials for shoulder conditions?’ A deﬁnition
of the domain was provided under each question.
Possible responses included ‘Yes’, ‘No’ and ‘Unsure/I
do not know’. Participants were encouraged to provide a
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rationale for their answer. We also asked participants
whether certain domains should be aggregated because
of conceptual overlap, and to suggest core domains that
may be missing.
We analysed round one data by calculating frequencies
of ‘Yes’, ‘No’ and ‘Unsure/I do not know’ for each
domain, based on responses from the total panel and
separately for each of the four stakeholder groups
(patients, researchers, clinicians, professionals working
as clinician and researcher). Those domains to which
more than two-thirds (at least 67%) of the total panel
chose the response option ‘Yes’ were considered for
inclusion in round two. Domains rated as important to
include by fewer than 67% of the total panel were
excluded unless there were any signiﬁcant arguments
provided in the rationale for responses that were against
the overall trend in frequencies. Participants’ suggestions
for the aggregation of certain domains and addition of
missing core domains were discussed and debated by all
authors via teleconference until consensus was reached.
One author (MJP or HH) summarised the decisions
made at each teleconference and fed this back to all
authors for review and reﬁnement.
The second round ran from 4 to 15 April 2016. A feed-
back report (see online supplementary ﬁle S4) summaris-
ing the level of consensus for each domain (overall and
Table 1 Potential core domains considered for shoulder disorder clinical trials (administered in Delphi round one)
Core area Domain
Life impact Pain intensity
Overall
At rest
With activity
On resisted movement
During the day
During the night
Temporal aspects of pain
Analgesic use
Physical functioning
Health-related quality of life
Social functioning
Recreation and leisure activity
Work ability
Depression
Anxiety
Fear avoidance beliefs
Sleep functioning
Fatigue
Satisfaction with treatment services
Global assessment of treatment success
Severity of the main complaint
Resource use Work productivity
Healthcare services
Non-healthcare services
Requiring reoperation or revision surgery
Pathophysiological manifestations Range of motion
Muscle strength
Muscle tone
Pain on palpation
Testing positive on specific tests during
physical examination
Shoulder instability
Scapular dysfunction
Proprioception
Weakness on movement
Shoulder swelling
Shoulder posture
Radiographic outcomes
Failure of surgery
Surgical process outcomes
Haemodynamic variables
Death Number of deaths
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per stakeholder group) from round one, but not the indi-
vidual comments to justify ratings, was emailed to all par-
ticipants, together with the second survey. Participants
were asked to judge whether each of the domains
brought forward from round one should indeed be con-
sidered core. Participants were informed that we chose to
aggregate certain domains based on round one com-
ments, and were then asked to rate whether the new
(aggregated) domain should be included in the COS.
Participants were also asked whether they agreed that all
of the domains excluded following round one should be
excluded from the COS. Possible responses were the
same as those in the round one survey. We deemed (a
priori) that consensus was reached if at least 67% of the
total panel and 67% of all stakeholder groups agreed that
a domain was core. The results of round two were
reviewed and discussed via teleconference.
RESULTS
Participants
In both rounds, 335 individuals were invited to partici-
pate (268 clinicians/researchers and 67 patients). In
the ﬁrst round, we received responses from 91 partici-
pants (50 clinicians/researchers and 41 patients;
response rate 27%) and in the second round, we
received responses from 96 participants (55 clini-
cians/researchers and 41 patients; response rate
29%). We could not determine how many participants
completed both Delphi rounds due to the anonymity
of the survey.
Demographic characteristics were collected only in
round one (table 2), so as not to burden respondents
with questions they may have previously answered. In
round one, the median age of the 91 participants was
51 years, and 49/91 (54%) were women. Most (56/91
(62%)) had a postgraduate degree. The 50 clinicians/
researchers worked in 13 countries (most were from the
UK and The Netherlands), and in several ﬁelds (ortho-
paedics and physiotherapy were most common). The
majority of clinicians/researchers (40/50 (80%)) had
conducted at least one clinical trial for shoulder disor-
ders. Of the patient respondents, almost half lived in the
Table 2 Characteristics of participants completing the
first Delphi round
Characteristic
Number
(%)
General characteristics (total panel) n=91
Gender
Women 49 (54)
Age
Median (IQR) 51 (40–58)
Highest education
Postgraduate degree (MSc, PhD) 56 (62)
Graduated from college/university 18 (20)
Graduated from high school 10 (11)
Graduated from primary school 1 (1)
Other 6 (7)
Stakeholder group
Clinician 19 (21)
Researcher 13 (14)
Professional working as clinician and
researcher
18 (20)
Patient 41 (45)
Clinician/researcher characteristics n=50
Country of work
UK 11 (22)
The Netherlands 8 (16)
Australia 7 (14)
USA 7 (14)
Canada 6 (12)
Sweden 2 (4)
Ireland 2 (4)
Turkey 2 (4)
Other (Brazil, Finland, Germany, Italy,
Norway)
5 (10)
Field of work
Orthopaedics 17 (34)
Physiotherapy 15 (30)
Rheumatology 5 (10)
Epidemiology 4 (8)
General practice/family medicine 3 (6)
Other (emergency medicine, physical
medicine and rehabilitation)
6 (12)
Research experience
Conducted at least one clinical trial for a
shoulder disorder
40 (80)
Conducted at least one systematic review
for a shoulder disorder
23 (46)
Developed or tested a measurement
instrument for a shoulder disorder
15 (30)
Participated in development of other COSs 20 (40)
Patient characteristics n=41
Country of residence
USA 18 (44)
UK 6 (15)
The Netherlands 4 (10)
Austria 3 (7)
Australia 2 (5)
Germany 2 (5)
Other (Belgium, Canada, Poland,
Slovakia)
4 (10)
Shoulder disorder history
Continued
Table 2 Continued
Characteristic
Number
(%)
Have sought healthcare for a shoulder
disorder at least once
36 (88)
Currently have a shoulder disorder 27 (66)
Duration of current shoulder disorder
Less than 6 weeks 2 (7)*
Between 6 and 12 weeks 3 (11)*
More than 3 months 15 (56)*
Not stated 7 (26)*
*Denominator is the number of patients who currently have a
shoulder disorder (n=27).
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USA (18/41 (44%)), while other participants lived in
nine other countries. Most patients (27/41 (66%)) were
currently experiencing shoulder pain (table 2).
Delphi round one
In total, 13 domains met our a priori criteria for inclu-
sion (ﬁgure 1). They consisted of ‘physical functioning’,
‘intensity of pain with activity’, ‘work ability’, ‘overall
pain intensity’, ‘night pain intensity’, ‘health-related
quality of life’, ‘rest pain intensity’, ‘temporal aspects of
pain’, ‘range of motion’, ‘recreation and leisure activity’,
‘global assessment of treatment success’, ‘muscle
strength’ and ‘sleep functioning’. However, a clear dis-
crepancy between the patients’ perspective and the total
panel responses was observed, since 22 domains met the
criteria for inclusion in the patient subgroup (see online
supplementary ﬁle 1, ﬁgure S1 and S2). Further, those
who worked as a researcher only were more likely than
all other stakeholders to consider most domains as not
core (see online supplementary ﬁle 1, ﬁgures S3–S5).
Several patients, clinicians and researchers emphasised
the overlap between all of the pain domains (eg, ‘inten-
sity of pain with activity’, ‘night pain’) (see all comments
to justify ratings in online supplementary ﬁle 5). To
address this, a proposal was formulated for the second
round to combine them all under one domain titled
‘pain’, deﬁned as ‘how much a person’s shoulder hurts,
reﬂecting the overall magnitude of the pain experience
(ie, at rest, during and after activity, at night)’. Several
clinicians and researchers suggested there was overlap
between activities of daily living (eg, bathing), recre-
ational activities and work ability. These comments were
addressed by creating a single domain called ‘physical
functioning’, with the following revised deﬁnition: ‘a
person’s ability to carry out daily physical activities
required to meet basic needs (eg, bathing, combing
hair), more complex activities that require a combin-
ation of skills (eg, driving a car), recreational/leisure
activities (eg, sports) and work tasks’. In addition, for
round two we combined different measures of psycho-
logical functioning (ie, depression, anxiety) into a single
domain based on comments from several clinicians and
researchers.
We proposed to exclude all domains that were consid-
ered by fewer than 67% of the total panel as core. An
exception to this was the domain ‘number of deaths’.
Despite being considered core by only 39% of the total
panel, we wanted participants to consider it again given
its obvious importance as an outcome event in shoulder
disorder trials, and due to the recommendation in the
OMERACT Filter 2.0 that deaths be measured in all
trials.10 Also, despite being rated highly by panellists in
Figure 1 Ratings by total panel
(n=91) of potential core domains
in the first Delphi round. The solid
black line depicts the consensus
threshold (67%).
Page MJ, et al. RMD Open 2016;2:e000380. doi:10.1136/rmdopen-2016-000380 5
Pain
group.bmj.com on December 22, 2016 - Published by http://rmdopen.bmj.com/Downloaded from 
round one, many comments emphasised that ‘range of
motion’ and ‘muscle strength’ are surrogate measures of
functional ability and do not necessarily relate well to
functional tasks participants report being able to
perform. These comments prompted a proposal for the
second round to exclude both domains. Participants did
not suggest any new domains.
Delphi round two
Across all stakeholder groups of participants, at least 67%
indicated that ‘pain’ (97%), ‘physical functioning’ (94%),
‘global assessment of treatment success’ (86%) and
‘health-related quality of life’ (79%) should be included
as core domains (ﬁgure 2). ‘Sleep functioning’ (70%)
and ‘psychological functioning’ (69%) also met the cri-
teria for inclusion based on responses from the total
panel. However, the threshold for inclusion of these two
domains was not met by all stakeholders, as 35% of clini-
cians/researchers were unsure about or preferred to
exclude ‘sleep functioning’, while 37% of patients were
unsure about or preferred to exclude ‘psychological func-
tioning’ (see online supplementary ﬁle 1, ﬁgure S6–S8).
Few participants (14%) considered it important to
include ‘number of deaths’ as a core domain. Comments
emphasised that death could be recorded as a serious
adverse event rather than as a separate domain.
Only 44% of the total panel agreed that ‘range of
motion’ and ‘muscle strength’ should be excluded from
the COS. Few participants provided rationale for their
responses. Of those that did, beliefs about the lack of
added value that these measures provide over self-
reported functional ability were most commonly
expressed. Further, 54% of the total panel agreed that
none of the domains from round one that we excluded
belonged in the COS. However, there was variation across
stakeholder groups on this question, with 100% of those
who worked only as researchers agreeing that they should
all be excluded, compared with 33% of patients. A recur-
ring comment was that ‘requiring reoperation or revision
surgery’ and ‘failure of surgery’ should be retained.
DISCUSSION
From a list of 41 potential core domains, we identiﬁed
four that the majority of participants (across all stake-
holder groups) considered core: ‘pain’, ‘physical func-
tioning’, ‘global assessment of treatment success’ and
‘health-related quality of life’. Two additional domains
—‘sleep functioning’ and ‘psychological functioning’—
also met the threshold for inclusion based on responses
from the total panel, but not among all stakeholders.
There was consensus that ‘number of deaths’ should not
be a core domain, but insufﬁcient agreement on
whether or not several other domains, including ‘range
of motion’ and ‘muscle strength’, were core domains.
There are several strengths of this research. We gener-
ated a comprehensive list of potential core domains
based on a prior literature review, as recommended by
the OMERACT8 and COMET14 initiatives. We obtained
participation from patients, and clinicians and research-
ers representing various scientiﬁc and clinical disci-
plines, which may enhance the generalisability of the
Figure 2 Ratings of core domains stratified by stakeholder group in the second Delphi round. The percentage of participants
agreeing that a domain is important to include is presented in the left panel. The percentage of participants agreeing that a
domain (or set of domains) should be excluded is presented in the right panel. The solid black line depicts the consensus
threshold (67%).
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results. Also, we allowed Delphi participants to provide
rationale for their domain ratings, which yielded convin-
cing arguments to aggregate certain domains. A limita-
tion is that the response rates to both Delphi rounds
were low, particularly for clinicians/researchers. The
majority of individuals in the sampling frame were corre-
sponding authors of shoulder trials indexed in PubMed
from 2006 to 2015. Not all of these authors may have had
a longstanding interest in shoulder disorders, and those
who switched their focus to other clinical conditions may
have been less likely to respond. Also, we do not know
how many participants completed both rounds of the
survey, and therefore cannot tell if the characteristics of
participants were similar in both rounds. While this can
be viewed as a minor drawback, we still maintained close
to equal numbers of our stakeholder groups in both
rounds. Further, we did not pilot the survey with patients
beforehand. Given that the concept of ‘outcomes/end-
points’ can be obscure,15 some patients may have misun-
derstood the purpose of the Delphi survey, or the
wording of certain domains and deﬁnitions, which could
have resulted in unreliable ratings from them. Another
limitation is that the sample size for some of the stake-
holder groups was small (eg, in round one, only 13 parti-
cipants worked as a researcher only, and in round two,
only 12 participants worked as a clinician only).
Therefore, the comparison of ratings by the different
stakeholder groups should be interpreted with caution.
The ﬁnding that nearly all Delphi participants rated
‘pain’ and ‘physical functioning’ as core domains is con-
sistent with what has been measured in published shoul-
der trials (these were measured in 90% and 71% of
trials, respectively.18 However, the high ratings of ‘global
assessment of treatment success’ and ‘health-related
quality of life’ contrasts with published literature, where
both domains were measured in only 15% of trials.18
The infrequent measurement of these domains may
have occurred because of unfamiliarity with appropriate
measurement instruments or assumptions that ‘pain’
and ‘physical functioning’ are the only PROMs that
matter. If ‘global assessment of treatment success’ and
‘health-related quality of life’ are included in the ﬁnal
COS for shoulder disorders, education on the value of
these domains will need to be prioritised during imple-
mentation strategies.
Based on suggestions from round one participants,
the deﬁnition of ‘physical functioning’ that we used in
round two covered activities of daily living (eg, bathing),
recreation/leisure activities and work ability. Despite
being considered core by 94% of participants, the
revised ‘physical functioning’ deﬁnition is incompatible
with some measurement instruments that purport to
measure this construct (eg, the disability subscale of the
Shoulder Pain And Disability Index16 only addresses
activities of daily living). It is possible that treating ‘phys-
ical functioning’ as a multidimensional domain may not
be feasible in practice, and instead the different compo-
nents may need to be treated as separate subdomains.
This will become clearer once we select measurement
instruments for the COS.
Implementation of a COS into clinical trials may depend
on the brevity of the set and the feasibility of measure-
ment.14 With this in mind, there are several reasons why it
may be appropriate to exclude domains where no consen-
sus was reached; for example, ‘range of motion’, ‘muscle
strength’ and surgical outcomes. Inclusion of ‘range of
motion’ and ‘muscle strength’ could lead to increased
research costs for shoulder disorder trials, since staff and
equipment are needed to perform the assessments. Also,
surgery-relevant outcomes should only be measured in sur-
gical trials (not all intervention trials, which, by deﬁnition, a
COS should apply to). We plan to discuss these issues
further during face-to-face meetings with various stake-
holders before reaching a ﬁnal decision.
We are aware of only one other study which has
sought perspectives on the most important domains to
measure in shoulder trials.17 Researchers asked 225 UK
orthopaedic surgeons, general practitioners and phy-
siotherapists to suggest which domain should be the
primary outcome in trials for adhesive capsulitis. The
most frequently suggested primary outcomes were func-
tion (59%), pain (48%) and range of motion (46%),
while less than 5% of respondents thought quality of
life, period to resolution, patient satisfaction, cost-
effectiveness and adverse events should be primary.
Having to nominate domains (without seeing a list of
potentially important ones) and being able to select
only one domain may explain why ‘global assessment of
treatment success’ and ‘health-related quality of life’
were rarely or never considered primary by clinicians in
the study by Rodgers et al. To the best of our knowledge,
no other study has been as comprehensive in scope as
ours, with its aim to identify a core set of domains for all
trials across various shoulder disorders, and consider-
ation of researcher and patient perspectives.
CONCLUSION
A majority of patients, clinicians and researchers identi-
ﬁed ‘pain’, ‘physical functioning’, ‘global assessment of
treatment success’ and ‘health-related quality of life’ as
important domains to include in a COS for shoulder dis-
orders. The value of several other domains, including
‘sleep functioning’, ‘psychological functioning’, ‘range
of motion’ and ‘muscle strength’, needs further consid-
eration. Our ﬁndings will be discussed in consensus
meetings at OMERACT 2016, where we plan to reach
agreement on a preliminary core set of domains for
shoulder disorder trials.18 In future, we plan to seek
endorsement of this core set from OMERACT, and to
select measurement instruments that must be adminis-
tered to cover each corresponding domain.
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